FR24C1032I2 - Dimere de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques - Google Patents

Dimere de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques

Info

Publication number
FR24C1032I2
FR24C1032I2 FR24C1032C FR24C1032C FR24C1032I2 FR 24C1032 I2 FR24C1032 I2 FR 24C1032I2 FR 24C1032 C FR24C1032 C FR 24C1032C FR 24C1032 C FR24C1032 C FR 24C1032C FR 24C1032 I2 FR24C1032 I2 FR 24C1032I2
Authority
FR
France
Prior art keywords
treatment
recombinant human
neurological diseases
csf dimer
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR24C1032C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evive Biotechnology Shanghai Ltd
Original Assignee
Evive Biotechnology Shanghai Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evive Biotechnology Shanghai Ltd filed Critical Evive Biotechnology Shanghai Ltd
Publication of FR24C1032I1 publication Critical patent/FR24C1032I1/fr
Application granted granted Critical
Publication of FR24C1032I2 publication Critical patent/FR24C1032I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR24C1032C 2010-05-25 2024-07-24 Dimere de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques Active FR24C1032I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2010101816235A CN102260343A (zh) 2010-05-25 2010-05-25 重组人g-csf二聚体在治疗神经损伤疾病中的用途
PCT/CN2011/074678 WO2011147319A1 (fr) 2010-05-25 2011-05-25 Dimère de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques

Publications (2)

Publication Number Publication Date
FR24C1032I1 FR24C1032I1 (fr) 2024-08-30
FR24C1032I2 true FR24C1032I2 (fr) 2025-06-20

Family

ID=45003325

Family Applications (1)

Application Number Title Priority Date Filing Date
FR24C1032C Active FR24C1032I2 (fr) 2010-05-25 2024-07-24 Dimere de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques

Country Status (15)

Country Link
US (2) US8557546B2 (fr)
EP (2) EP2576624B1 (fr)
JP (1) JP6114186B2 (fr)
CN (3) CN102260343A (fr)
AU (1) AU2011257734B2 (fr)
CA (1) CA2800688C (fr)
DK (2) DK3121198T3 (fr)
ES (2) ES2611151T3 (fr)
FI (1) FIC20240027I1 (fr)
FR (1) FR24C1032I2 (fr)
HU (2) HUE031872T2 (fr)
NL (1) NL301285I2 (fr)
PL (1) PL2576624T3 (fr)
PT (1) PT2576624T (fr)
WO (1) WO2011147319A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637637B2 (en) * 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
CN103717614A (zh) * 2011-08-09 2014-04-09 普罗法尔马封闭式股份公司 重组蛋白质的衍生物、粒细胞集落刺激因子的同多聚体及其制备方法
CA2876737A1 (fr) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
LT6161B (lt) * 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
EP2957294A1 (fr) * 2014-06-20 2015-12-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. GCSF pour utilisation dans le traitement de la suppression immunitaire neurogène et/ou la prévention de complications médicales associées
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
US20260053742A1 (en) 2022-08-19 2026-02-26 Evive Biotechnology (Shanghai) Ltd Formulations comprising g-csf and uses thereof
AU2024309736A1 (en) 2023-06-30 2026-01-15 Evive Biotechnology (Shanghai) Ltd G-csf dimer for use in the treatment or prevention of chemotherapy or radiotherapy induced neutropenia

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954004B2 (ja) 1991-12-26 2007-08-08 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
AU4658596A (en) 1995-02-03 1996-08-21 G.D. Searle & Co. Novel c-mpl ligands
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000024758A1 (fr) 1998-10-26 2000-05-04 Ludwig Institute For Cancer Research Molecules d'acide nucleique isolees codant pour des facteurs inductibles derives de lymphocytes t (tif), proteines codees et leur utilisation
US6274710B1 (en) 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US7754855B1 (en) * 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
GB0024442D0 (en) 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
WO2002036626A1 (fr) * 2000-11-02 2002-05-10 Maxygen Aps Polypeptides multimeres comportant une seule chaine
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
CN100515491C (zh) 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
WO2008137571A1 (fr) 2007-05-01 2008-11-13 Florida Atlantic University Procédés de traitement de maladies neurodégénératives
WO2008147534A1 (fr) 2007-05-22 2008-12-04 Maxygen Holdings Ltd. Procédé de traitement de neutropénie par l'administration d'une variante de facteur stimulant les colonies de granulocytes multi-pégylés (g-csf)
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
EP2185583A2 (fr) 2007-08-03 2010-05-19 Asterion Limited Facteur de stimulation des colonies de granulocytes
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
KR101867606B1 (ko) 2007-11-07 2018-06-18 제넨테크, 인크. 미생물 질환의 치료를 위한 조성물 및 방법
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2011205531B2 (en) 2010-01-13 2013-10-10 Amgen Inc. IL-22-Fc and hepcidin activity
LT2010013A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas
LT2010012A (lt) 2010-02-10 2011-08-25 Uab Profarma, , Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用

Also Published As

Publication number Publication date
CN102260343A (zh) 2011-11-30
PT2576624T (pt) 2016-10-31
WO2011147319A1 (fr) 2011-12-01
NL301285I2 (nl) 2024-08-21
CN102906120B (zh) 2015-03-04
EP2576624B1 (fr) 2016-08-31
US9273108B2 (en) 2016-03-01
HUE031872T2 (en) 2017-08-28
FR24C1032I1 (fr) 2024-08-30
US8557546B2 (en) 2013-10-15
AU2011257734B2 (en) 2015-06-11
CN102906120A (zh) 2013-01-30
FIC20240027I1 (fi) 2024-07-30
JP6114186B2 (ja) 2017-04-12
EP3121198A1 (fr) 2017-01-25
EP2576624A4 (fr) 2013-11-13
CA2800688A1 (fr) 2011-12-01
HUS2400027I1 (hu) 2024-08-28
CA2800688C (fr) 2018-05-15
ES2611151T3 (es) 2017-05-05
JP2013530148A (ja) 2013-07-25
US20140004076A1 (en) 2014-01-02
DK2576624T3 (en) 2016-11-14
DK3121198T3 (da) 2019-10-28
EP3121198B1 (fr) 2019-08-14
PL2576624T3 (pl) 2017-02-28
US20110293554A1 (en) 2011-12-01
AU2011257734A1 (en) 2012-12-20
ES2750730T3 (es) 2020-03-26
EP2576624A1 (fr) 2013-04-10
CN104710535A (zh) 2015-06-17
CN104710535B (zh) 2018-10-16

Similar Documents

Publication Publication Date Title
FR24C1032I2 (fr) Dimere de g-csf humaine recombinante et son emploi dans le traitement de maladies neurologiques
FR23C1010I2 (fr) Anticorps bispecifiques anti-ang-2/anti-vegf et leur utilisation dans le traitement des maladies vasculaires oculaires
EP2672927A4 (fr) Occlusion d'appendice auriculaire et traitement de l'arythmie
EP2916827A4 (fr) Procédés et dispositifs pour le traitement de maladies oculaires chez des sujets humains
EP2684167A4 (fr) Compositions et méthodes utiles dans le traitement de maladies
EP3686200A3 (fr) Composés hétérocycles bicycliques et leurs utilisations en thérapie
EP2709672A4 (fr) Compositions et méthodes pour le traitement de maladies de la rétine
HRP20192130T1 (hr) Kombinacijska terapija za liječenje pacijenata s neurološkim poremećajima i moždanim udarom
EP2793993A4 (fr) Récupération et traitement d'embryons humains formés in vivo
EP2774616A4 (fr) Application de roseburia dans le traitement et la prévention de maladies liées à l'obésité
IL236920B (en) Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals
EP2459510A4 (fr) Acides gras hydroxy et leurs utilisations dans le traitement et le diagnostic de maladies
EP2613786A4 (fr) Traitement de maladies
EP2613795A4 (fr) Traitement de maladies
PT3087178T (pt) Método para produzir oxalato oxidases que têm atividade ótica próxima ao ph fisiológico e utilização de tais oxalato oxidases recombinantes no tratamento de doenças relacionadas com oxalato
IL261742B (en) Human antibodies and their diagnostic and therapeutic uses for the treatment of neurological diseases
IL251543A0 (en) Use of a topical gel composition in the manufacture of a medicament for the prevention or treatment of a skin disorder
EP2904010A4 (fr) Traitement des maladies vasculaires et de leurs complications
EP2949651A4 (fr) Benzothiazoles substitués et leurs appllications thérapeutiques pour le traitement de maladies humaines
EP2707486A4 (fr) Diagnostic et traitement de l'ataxie de friedreich
EP2642989A4 (fr) Méthodes de traitement de maladies oculaires associées à une inflammation et à une prolifération vasculaire
EP2413958A4 (fr) Cytokines et neuroantigènes utilisés dans le traitement de maladies immunitaires
GB201215873D0 (en) Compositions and methods relating to the treatment of allergy and allergic diseases
EP2838509A4 (fr) Formulations et procédés pour le traitement de maladies inflammatoires de la peau
EP2517014A4 (fr) Marqueur précoce de la protéinurie chez les patients traités par un traitement anti-vegf